Epizyme Collaborates with Celgene to Develop Epigenetics-Based Targeted Cancer Therapeutics
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 5 (Table of Contents)
Published: 10 May-2012
DOI: 10.3833/pdr.v2012.i5.1739 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Celgene has agreed to pay Epizyme US$90 M upfront, including an equity investment, as part of a deal to discover, develop and commercialise histone methyltransferase (HMT) inhibitors for patients with genetically defined cancers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS